Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xynomic Pharma In-Licenses Global Rights to HDAC Inhibitor for Cancer

publication date: Feb 24, 2017
Xynomic Pharma, a US-China oncology startup, has acquired exclusive global rights to abexinostat, an HDAC inhibitor targeting hematological and solid tumor cancers with, Xynomic believes, best-in-class potential. Xynomic did not disclose the source of the candidate, though abexinostat was previously being developed by Pharmacyclics. AbbVie paid $21 billion to acquire Pharmacyclics in 2015. Abexinostat seems to be the first in-licensing for Xynomic, which is headquartered in Wyoming with "major operations" in Shanghai. No financial details of the agreement were released. More details....

Stock Symbols: (NYSE: ABBV)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital